17 Capital Partners LLC Buys 2,881 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

17 Capital Partners LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 97.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,846 shares of the company’s stock after buying an additional 2,881 shares during the quarter. 17 Capital Partners LLC’s holdings in Neurocrine Biosciences were worth $674,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. 1832 Asset Management L.P. raised its position in shares of Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after buying an additional 504,400 shares in the last quarter. AQR Capital Management LLC raised its position in Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after purchasing an additional 228,444 shares in the last quarter. Vanguard Group Inc. lifted its stake in Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after purchasing an additional 220,598 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at $30,342,000. Finally, Renaissance Technologies LLC increased its stake in shares of Neurocrine Biosciences by 9.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after purchasing an additional 216,500 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 1.4 %

NBIX opened at $125.74 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $103.63 and a twelve month high of $157.98. The company has a fifty day moving average of $118.43 and a 200-day moving average of $133.11. The stock has a market cap of $12.73 billion, a PE ratio of 33.71 and a beta of 0.35.

Insiders Place Their Bets

In related news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total value of $2,120,358.00. Following the completion of the sale, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at $4,741,180.64. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,063 shares of company stock worth $7,023,330. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on NBIX. Robert W. Baird raised their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Oppenheimer raised their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Raymond James reiterated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Finally, Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.